This website is intended for Healthcare Professionals in the U.S.

Enroll your Patients for One-to-One Access Support

Learn more about comprehensive support from BioMarin

At BioMarin, we are committed to serving the needs of patients, families, and practices by providing rapid access to therapeutic treatment, disease education, and support services.

BioMarin RareConnections™ provides patients on PALYNZIQ with personalized Case Management and has Field Reimbursement Managers available to provide reimbursement education to your clinic, product access education, and logistics support.

biomarin rare connections

BioMarin RareConnections™

Learn how a Case Manager will work with clinic teams and support patients by confirming insurance benefits, providing financial assistance options, and coordinating shipment of medication.

Learn More

BioMarin RareConnectionsTM helps patients gain access to therapy throughout their treatment journey, including:

  • Personalized financial support
    BioMarin RareConnections Case Managers work one-to-one with patients and their families; BioMarin RareConnections Field Reimbursement Managers work one-to-one with your clinic.
  • Product access education and support
    Help for patients prescribed PALYNZIQ® (pegvaliase-pqpz) so they can navigate the insurance process and understand coverage options to gain access to treatment Financial assistance programs for eligible patients, such as co-pay assistance* Information about payer requirements your clinic needs to seek access for treatment coverage for patients.
  • Logisitics support
    Case Managers assist with directing the prescription to the appropriate specialty pharmacy and coordinating the shipment to the patient’s home.

Contact BioMarin RareConnectionsTM at 1-833-PKU-CARE(1-833-758-2273) or email support@biomarin-rareconnections.com

BioMarin Co-Pay logo

Co-Pay Assistance Program

Explore options available that may help patients pay for PALYNZIQ® (pegvaliase-pqpz) Injection.

Learn More

BioMarin is committed to helping your patients with co-pay or out-of-pocket costs for PALYNZIQ. With the PALYNZIQ Co-Pay Assistance Program:

99% of participating patients paid $0 out-of-pocket for their prescription
  • The PALYNZIQ Co-Pay Assistance Program will cover all co-pay costs related to both PALYNZIQ® (pegvaliase-pqpz) Injection and auto-injectable epinephrine prescriptions, up to the annual maximum, for as long as patients remain on therapy
  • Eligible patients will receive 3 fills of auto-injectable epinephrine per year at no additional cost

In order to qualify for BioMarin’s Co-Pay Assistance Program, your patients must meet the following criteria:

  • Covered by commercial (private) insurance
  • Not a participant in a federal or state-funded healthcare program, including but not limited to Medicare, Medicaid, VA/DoD, TRICARE, and Medigap
  • Live in the United States or Puerto Rico

*Valid only for those with commercial insurance. Offer not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicare, Medicaid, or any other federal or state program (including any state prescription drug assistance programs) (eg, VA, DoD, TRICARE), for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third-party payer, whether public or private. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. Co-payment assistance under the Program is not transferable. BioMarin Pharmaceutical Inc. reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This program is subject to termination or modification at any time.

†Based on 2018 and 2019 co-pay program data.

‡The PALYNZIQ Co-Pay Assistance Program will cover up to $18,200 in assistance per calendar year for eligible patients. Some restrictions apply.

BioMarin Clinical co-ordinators logo

BioMarin Clinical Coordinators

Review details of the one-on-one product support and education your patients will receive from a BioMarin Clinical Coordinator.

Learn More

BioMarin Clinical Coordinators are there to support patients’ treatment journeys and help them fit BioMarin treatment into their lifestyles. More specifically, they will provide:

  • Support throughout therapy
    As your patients get started on the treatment plan the clinic sets up, their Clinical Coordinator will be there to answer questions they have about their therapy. Clinical Coordinators are also available for face-to-face or virtual visits.
  • Education
    Patients’ Clinical Coordinators will partner with them to provide information about PKU, their BioMarin therapy, how to take it, and dietary options. They also offer grocery store tours to show patients foods that meet their dietary needs.
  • Help staying on track
    Clinical Coordinators will help provide patients with reminders to stay on track according to the treatment plan the clinic team sets up.

PALYNZIQ REMS Program

PALYNZIQ is only available through the PALYNZIQ REMS program to mitigate the risk of anaphylaxis. Your office must become REMS-certified before you can begin to prescribe PALYNZIQ.

Learn More

Ready to enroll a patient?

We have everything you need to get started in one convenient location.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF ANAPHYLAXIS

  • Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during treatment
  • Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient’s and observer’s (if applicable) ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable epinephrine, if needed
  • Consider having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis during PALYNZIQ treatment. If an adult observer is needed, the observer should be present during and for at least 60 minutes after PALYNZIQ administration, should be able to administer auto-injectable epinephrine, and call for emergency medical support upon its use
  • Prescribe auto-injectable epinephrine. Prior to the first dose, instruct the patient and observer (if applicable) on its appropriate use. Instruct the patient to seek immediate medical care upon its use. Instruct patients to carry auto-injectable epinephrine with them at all times during PALYNZIQ treatment
  • PALYNZIQ is available only through a restricted program called PALYNZIQ REMS (Risk Evaluation and Mitigation Strategy). Further information, including a list of qualified pharmacies, is available at www.PALYNZIQREMS.com or by telephone at 1-855-758-REMS (1-855-758-7367)

WARNINGS AND PRECAUTIONS

Anaphylaxis

  • Signs and symptoms of anaphylaxis reported include syncope, hypotension, hypoxia, dyspnea, wheezing, chest discomfort/chest tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue), throat tightness, skin flushing, rash, urticaria, pruritus, and gastrointestinal symptoms (vomiting, nausea, diarrhea)
  • Anaphylaxis generally occurred within 1 hour after injection; however, delayed episodes occurred up to 48 hours after PALYNZIQ administration
  • Consider having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis during PALYNZIQ treatment. If an adult observer is needed, the observer should be present during and for at least 60 minutes after PALYNZIQ administration, should be able to administer auto-injectable epinephrine, and call for emergency medical support upon its use
  • Anaphylaxis requires immediate treatment with auto-injectable epinephrine. Prescribe auto-injectable epinephrine to all patients receiving PALYNZIQ and instruct patients to carry auto-injectable epinephrine with them at all times during PALYNZIQ treatment. Prior to the first dose, instruct the patient and observer (if applicable) on how to recognize the signs and symptoms of anaphylaxis, how to properly administer auto-injectable epinephrine, and to seek immediate medical care upon its use. Consider the risks associated with auto-injectable epinephrine use when prescribing PALYNZIQ. Refer to the auto-injectable epinephrine prescribing information for complete information
  • Consider the risks and benefits of readministering PALYNZIQ following an episode of anaphylaxis. If the decision is made to readminister PALYNZIQ, administer the first dose under the supervision of a healthcare provider equipped to manage anaphylaxis and closely observe the patient for at least 60 minutes following the dose. Subsequent PALYNZIQ dose titration should be based on patient tolerability and therapeutic response
  • Consider premedication with an H1-receptor antagonist, H2-receptor antagonist, and/or antipyretic prior to PALYNZIQ administration based upon individual patient tolerability

Other Hypersensitivity Reactions

  • Hypersensitivity reactions other than anaphylaxis have been reported in 204 of 285 (72%) patients treated with PALYNZIQ in clinical trials
  • Management of hypersensitivity reactions should be based on the severity of the reaction, recurrence of the reaction, and the clinical judgment of the healthcare provider, and may include dosage adjustment, temporary drug interruption, or treatment with antihistamines, antipyretics, and/or corticosteroids

ADVERSE REACTIONS

  • The most common adverse reactions (at least 20% of patients in either treatment phase) were injection site reactions, arthralgia, hypersensitivity reactions, headache, generalized skin reactions lasting at least 14 days, nausea, abdominal pain, vomiting, cough, oropharyngeal pain, pruritus, diarrhea, nasal congestion, fatigue, dizziness, and anxiety
  • Of the 285 patients exposed to PALYNZIQ in an induction/titration/maintenance regimen in clinical trials, 44 (15%) patients discontinued treatment due to adverse reactions. The most common adverse reactions leading to treatment discontinuation were hypersensitivity reactions (6% of patients) including anaphylaxis (3% of patients), angioedema (1% of patients), arthralgia (4% of patients), generalized skin reactions lasting at least 14 days (2% of patients), and injection site reactions (1% of patients)
  • The most common adverse reactions leading to dosage reduction were arthralgia (15% of patients), hypersensitivity reactions (9% of patients), injection site reactions (4% of patients), alopecia (3% of patients), and generalized skin reactions lasting at least 14 days (2% of patients)
  • The most common adverse reactions leading to temporary drug interruption were hypersensitivity reactions (14% of patients), arthralgia (13% of patients), anaphylaxis (4% of patients), and injection site reactions (4% of patients)
  • Angioedema and serum sickness: In clinical trials, 22 out of 285 (8%) patients experienced 45 episodes of angioedema (symptoms included: pharyngeal edema, swollen tongue, lip swelling, mouth swelling, eyelid edema, and face edema) occurring independent of anaphylaxis. In clinical trials, serum sickness was reported in 7 out of 285 (2%) patients

Blood Phenylalanine Monitoring and Diet

  • Obtain blood Phe concentrations every 4 weeks until a maintenance dosage is established. Periodically monitor blood Phe concentrations during maintenance therapy
  • Counsel patients to monitor dietary protein and Phe intake, and adjust as directed by their healthcare provider

DRUG INTERACTIONS

Effect of PALYNZIQ on Other PEGylated Products

  • In a single-dose study of PALYNZIQ in adult patients with PKU, two patients receiving concomitant injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced a hypersensitivity reaction. One of the two patients experienced anaphylaxis
  • The clinical effects of concomitant treatment with different PEGylated products are unknown. Monitor patients treated with PALYNZIQ and concomitantly with other PEGylated products for hypersensitivity reactions including anaphylaxis

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation

  • PALYNZIQ may cause fetal harm when administered to a pregnant woman
  • Advise women who are exposed to PALYNZIQ during pregnancy or who become pregnant within one month following the last dose of PALYNZIQ that there is a pregnancy surveillance program that monitors pregnancy outcomes. Healthcare providers should report PALYNZIQ exposure and encourage these patients to report their pregnancy to BioMarin (1-866-906-6100)
  • Monitor blood Phe levels in breastfeeding women treated with PALYNZIQ

Pediatric Use

  • The safety and effectiveness of PALYNZIQ in pediatric patients have not been established

Geriatric Use

  • Clinical studies of PALYNZIQ did not include patients aged 65 years and older

You are encouraged to report suspected adverse reactions to BioMarin at 1-866-906-6100, or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, with Boxed Warning for risk of anaphylaxis, and Medication Guide here.

INDICATION
PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.